AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Unlike others in its class, tirzepatide targets two hormones — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This double action makes it particularly ...

HT-6184, a first-in-class, selective, and orally bioavailable inhibitor of the NEK7/NLRP3 inflammasome, is undergoing preclinical evaluation in combination with the GLP-1 agonist semaglutide.

The new menu includes five smoothies “created to assist the millions of Americans currently taking prescription GLP-1 medications" Sabrina Weiss is the Editorial Assistant of PEOPLE's food ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to their astronomical pricing, drug shortages, compounding disputes ...

1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not associated with increased risks of pulmonary aspiration during upper ...

The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ... ratio of 39.7 is far from cheap. By comparison, the average P/E for the S&P 500 ...

Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication ... shares of Novo look attractive right now. As the chart illustrates, the company's P/E multiple has ...

In a world increasingly focused on health and wellness, finding effective solutions for weight management can be challenging. That’s where GlucoBoost GLP-1 Booster comes into play. This innovative ...